Contemporary management of patients with type 1 diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 3, 2010, Pages 573-593

  Mehta, Sanjeev N ^a,b   Wolfsdorf, Joseph I ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Diabetes; Intensive therapy; Management; Outcomes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN;

BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CARBOHYDRATE INTAKE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DIET THERAPY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INJECTION SITE STINGING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MENTAL DEVELOPMENT; MORNING DOSAGE; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REVIEW; SELF MONITORING; SKIN INFECTION;

EID: 77955738395     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.05.002     Document Type: Review

References (114)

1. Skyler J.S., Lasky I.A., Skyler D.L., et al. Home blood glucose monitoring as an aid in diabetes management. Diabetes Care 1978, 1:150-157.
2. Sonksen P.H., Judd S.L., Lowy C. Home monitoring of blood-glucose. Method for improving diabetic control. Lancet 1978, 1:729-732.
3. The DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
4. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
5. Lachin J.M., Genuth S., Nathan D.M., et al. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008, 57:995-1001.
6. The Diabetes Control and Complications Trial Research Group Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18:1415-1427.
7. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997, 46:271-286.
8. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18:1468-1478. The Diabetes Control and Complications Trial Research Group.
9. Wegner S.E., Lathren C.R., Humble C.G., et al. A medical home for children with insulin-dependent diabetes: comanagement by primary and subspecialty physicians-convergence and divergence of opinions. Pediatrics 2008, 122:e383-e387.
10. The Diabetes Control and Complications Research Group Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996, 276:1409-1415.
11. Herman W.H., Dasbach E.J., Songer T.J., et al. The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinol Metab Clin North Am 1997, 26:679-695.
12. The team approach. Intensive diabetes management 2009, 15-28. American Diabetes Association, Alexandria (VA). 4th edition. J.I. Wolfsdorf (Ed.).
13. Clar C., Waugh N., Thomas S. Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus. Cochrane Database Syst Rev 2007, 2. CD004099.
14. American Diabetes Association Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S62.
15. Rodbard H.W., Blonde L., Braithwaite S.S., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(Suppl 1):1-68.
16. National Collaborating Centre for Chronic Conditions Type 1 diabetes in adults: National clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians Press Available at:, Updated September 10, 2004. Accessed January 20, 2010. http://www.nice.org.uk/CG15.
17. National Collaborating Centre for Women's and Children's Health Type 1 diabetes: diagnosis and management of type 1 diabetes in children and young people. Royal College of Physicians Press Available at:, Updated June 2009. Accessed January 20, 2010. http://www.nice.org.uk/CG15.
18. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32:S1-S201.
19. Pihoker C., Forsander G., Wolfsdorf J., et al. The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr Diabetes 2009, 10(Suppl 12):58-70.
20. Smart C., Aslander-van Vliet E., Waldron S. Nutritional management in children and adolescents with diabetes. Pediatr Diabetes 2009, 10(Suppl 12):100-117.
21. Australasian Paediatric Endocrine Group Clinical practice guidelines: Type 1 diabetes in children and adolescents. National Health and Medical Research Council Available at:, Updated March 9, 2005. Accessed January 20, 2010. http://www.nhmrc.gov.au/publications/synopses/cp102syn.htm.
22. Schade D.S., Santiago J.V., Skyler J., et al. Insulin secretion in non-diabetic and insulin-dependent subjects. Intensive insulin therapy 1983, Excerpta Medica, Princeton (NJ), p. 23-35.
23. Hirsch I.B. Insulin analogues. N Engl J Med 2005, 352:174-183.
24. Rachmiel M., Perlman K., Daneman D. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am 2005, 52:1651-1675.
25. Plank J., Wutte A., Brunner G., et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002, 25:2053-2057.
26. Holleman F., Hoekstra J.B. Insulin lispro. N Engl J Med 1997, 337:176-183.
27. Holmes G., Galitz L., Hu P., et al. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005, 60:469-476.
28. Howey D.C., Bowsher R.R., Brunelle R.L., et al. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994, 43:396-402.
29. Danne T., Aman J., Schober E., et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003, 26:2359-2364.
30. Swan K.L., Weinzimer S.A., Dziura J.D., et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008, 31:44-46.
31. Dimitriadis G.D., Gerich J.E. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983, 6:374-377.
32. Lean M.E., Ng L.L., Tennison B.R. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J (Clin Res Ed) 1985, 290:105-108.
33. Deeb L.C., Holcombe J.H., Brunelle R., et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001, 108:1175-1179.
34. Brunelle B.L., Llewelyn J., Anderson J.H., et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998, 21:1726-1731.
35. Siebenhofer A., Plank J., Berghold A., et al. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004, 47:1895-1905.
36. Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005, 165:1337-1344.
37. Siebenhofer A., Plank J., Berghold A., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006, 2. CD003287.
38. Singh S.R., Ahmad F., Lal A., et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 180:385-397.
39. Siebenhofer A., Jeitler K., Berghold A., et al. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2009, 26:311-312.
40. Bode B., Weinstein R., Bell D., et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002, 25:439-444.
41. Gale E.A. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000, 17:209-214.
42. Binder C., Lauritzen T., Faber O., et al. Insulin pharmacokinetics. Diabetes Care 1984, 7:188-199.
43. Vague P., Selam J.L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003, 26:590-596.
44. Standl E., Lang H., Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004, 6:579-588.
45. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005, 7:73-82.
46. Garg S.K., Hirsch I.B., Skyler J.S. Insulin glargine and cancer-an unsubstantiated allegation. Diabetes Technol Ther 2009, 11:473-476.
47. The DCCT Research Group Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18:361-376.
48. Kobayashi T., Nakanishi K., Murase T., et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996, 45:622-626.
49. Hirsch I.B. Intensive treatment of type 1 diabetes. Med Clin North Am 1998, 82:689-719.
50. Paris C.A., Imperatore G., Klingensmith G., et al. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. J Pediatr 2009, 155:183-189.
51. Holl R.W., Swift P.G., Mortensen H.B., et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr 2003, 162:22-29.
52. Danne T., Mortensen H.B., Hougaard P., et al. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group. Diabetes Care 2001, 24:1342-1347.
53. de Beaufort C.E., Swift P.G., Skinner C.T., et al. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidore Study Group on Childhood Diabetes. Diabetes Care 2007, 30:2245-2250.
54. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569.
55. White N.H., Cleary P.A., Dahms W., et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001, 139:804-812.
56. Weinzimer S.A., Sikes K.A., Steffen A.T., et al. Insulin pump treatment of childhood type 1 diabetes. Pediatr Clin North Am 2005, 52:1677-1688.
57. Pickup J.C., Keen H., Parsons J.A., et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978, 1:204-207.
58. Tamborlane W.V., Sherwin R.S., Genel M., et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979, 300:573-578.
59. Boland E.A., Grey M., Oesterle A., et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999, 22:1779-1784.
60. Wood J.R., Laffel L.M.B. Technology and intensive management in youth with type 1 diabetes: State of the art. Curr Diab Rep 2007, 7:104-113.
61. Danne T., Lange K., Kordonouri O. New developments in the treatment of type 1 diabetes in children. Arch Dis Child 2007, 92:1015-1019.
62. Eugster E.A., Francis G. Position statement: continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics 2006, 118:e1244-e1249.
63. Phillip M., Battelino T., Rodriguez H., et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007, 30:1653-1662.
64. Weissberg-Benchell J., Antisdel-Lomaglio J., Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003, 26:1079-1087.
65. Jeitler K., Horvath K., Berghold A., et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008, 51:941-951.
66. Retnakaran R., Hochman J., DeVries J.H., et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004, 27:2590-2596.
67. Nimri R., Weintrob N., Benzaquen H., et al. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006, 117:2126-2131.
68. Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002, 324:705.
69. Colquitt J.L., Green C., Sidhu M.K., et al. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004, 8:iii-xii. 1-171.
70. Fatourechi M.M., Kudva Y.C., Murad M.H., et al. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009, 94:729-740.
71. Bode B.W., Steed R.D., Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996, 19:324-327.
72. Plotnick L.P., Clark L.M., Brancati F.L., et al. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003, 26:1142-1146.
73. Willi S.M., Planton J., Egede L., et al. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003, 143:796-801.
74. Springer D., Dziura J., Tamborlane W.V., et al. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. J Pediatr 2006, 149:227-232.
75. Pickup J.C., Sutton A.J. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008, 25:765-774.
76. Cogen F.R., Henderson C., Hansen J.A., et al. Pediatric quality of life in transitioning to the insulin pump: does prior regimen make a difference?. Clin Pediatr (Phila) 2007, 46:777-779.
77. Guerci B., Meyer L., Salle A., et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999, 84:2673-2678.
78. Egger M., Davey S.G., Stettler C., et al. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997, 14:919-928.
79. Burdick J., Chase H.P., Slover R.H., et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004, 113:e221-e224.
80. Conwell L.S., Pope E., Artiles A.M., et al. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr 2008, 152:622-628.
81. Schifferdecker E., Schmidt K., Boehm B.O., et al. Long-term compliance of intensified insulin therapy. Diabetes Res Clin Pract 1994, 23:17-23.
82. Wood J.R., Moreland E.C., Volkening L.K., et al. Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care 2006, 29:2355-2360.
83. Lenhard M.J., Reeves G.D. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001, 161:2293-2300.
84. Litton J., Rice A., Friedman N., et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002, 141:490-495.
85. Kaufman F.R., Halvorson M., Fisher L., et al. Insulin pump therapy in type 1 pediatric patients. J Pediatr Endocrinol Metab 1999, 12(Suppl 3):759-764.
86. Pickup J., Keen H. Continuous subcutaneous insulin infusion in type 1 diabetes. BMJ 2001, 322:1262-1263.
87. Weinzimer S.A., Ahern J.H., Doyle E.A., et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004, 114:1601-1605.
88. Gunther A.L., Liese A.D., Bell R.A., et al. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. Hypertension 2009, 53:6-12.
89. Bantle J.P., Wylie-Rosett J., Albright A.L., et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008, 31(Suppl 1):S61-S78.
90. Khakpour D., Thomson L. The nutrition specialist on the diabetes management team. Clin Diabetes 1998, 16:21-22.
91. Halfon P., Belkhadir J., Slama G. Correlation between amount of carbohydrate in mixed meals and insulin delivery by artificial pancreas in seven IDDM subjects. Diabetes Care 1989, 12:427-429.
92. Wheeler M.L., Pi-Sunyer F.X. Carbohydrate issues: type and amount. J Am Diet Assoc 2008, 108:S34-S39.
93. Anderson E.J., Richardson M., Castle G., et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc 1993, 93:768-772.
94. Wolever T.M., Hamad S., Chiasson J.L., et al. Day-to-day consistency in amount and source of carbohydrate associated with improved blood glucose control in type 1 diabetes. J Am Coll Nutr 1999, 18:242-247.
95. Brand-Miller J., Hayne S., Petocz P., et al. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003, 26:2261-2267.
96. Delahanty L.M. Clinical significance of medical nutrition therapy in achieving diabetes outcomes and the importance of the process. J Am Diet Assoc 1998, 98:28-30.
97. Pastors J.G., Warshaw H., Daly A., et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002, 25:608-613.
98. Mehta S.N., Volkening L.K., Anderson B.J., et al. Dietary behaviors predict glycemic control in youth with type 1 diabetes. Diabetes Care 2008, 31:1318-1320.
99. Mehta S.N., Quinn N., Volkening L.K., et al. Impact of carbohydrate counting on glycemic control in children with type 1 diabetes. Diabetes Care 2009, 32:1014-1016.
100. Smart C.E., Ross K., Edge J.A., et al. Children and adolescents on intensive insulin therapy maintain postprandial glycaemic control without precise carbohydrate counting. Diabet Med 2009, 26:279-285.
101. Bishop F.K., Maahs D.M., Spiegel G., et al. The Carbohydrate Counting in Adolescents with Type 1 Diabetes (CCAT) study. Diabetes Spectr 2009, 22:56-62.
102. Mayer-Davis E.J., Nichols M., Liese A.D., et al. Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc 2006, 106:689-697.
103. Overby N.C., Flaaten V., Veierod M.B., et al. Children and adolescents with type 1 diabetes eat a more atherosclerosis-prone diet than healthy control subjects. Diabetologia 2007, 50:307-316.
104. Saito M., Kuratsune H., Nitta H., et al. Plasma lipid levels and nutritional intake in childhood- and adolescence-onset young type 1 diabetic patients in Japan. Diabetes Res Clin Pract 2006, 73:29-34.
105. Liu L.L., Lawrence J.M., Davis C., et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth Study. Pediatr Diabetes 2010, 11(1):4-11.
106. Mehta S.N., Haynie D.L., Higgins L.A., et al. Emphasis on carbohydrates may negatively influence dietary patterns in youth with type 1 diabetes. Diabetes Care 2009, 32:2174-2176.
107. Karter A.J., Ackerson L.M., Darbinian J.A., et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001, 111:1-9.
108. Levine B.S., Anderson B.J., Butler D.A., et al. Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes. J Pediatr 2001, 139:197-203.
109. Nathan D.M., McKitrick C., Larkin M., et al. Glycemic control in diabetes mellitus: have changes in therapy made a difference?. Am J Med 1996, 100:157-163.
110. Strowig S.M., Raskin P. Improved glycemic control in intensively treated type 1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses. Diabetes Care 1998, 21:1694-1698.
111. Evans J.M., Newton R.W., Ruta D.A., et al. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ 1999, 319:83-86.
112. Dorchy H., Roggemans M.P., Willems D. Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience. Diabetes Care 1997, 20:2-6.
113. Nordwall M., Bojestig M., Arnqvist H.J., et al. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes-the Linkoping Diabetes Complications Study. Diabetologia 2004, 47:1266-1272.
114. Nathan D.M., Zinman B., Cleary P.A., et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005). Arch Intern Med 2009, 169:1307-1316.